Show simple item record

dc.contributor.authorYu, DongHoon
dc.contributor.authorWagner, Sabrina
dc.contributor.authorSchütz, Martin
dc.contributor.authorJeon, Yeejin
dc.contributor.authorSeo, Mooyoung
dc.contributor.authorKim, Jaeseung
dc.contributor.authorBrückner, Nadine
dc.contributor.authorKicuntod, Jintawee
dc.contributor.authorTillmanns, Julia
dc.contributor.authorWangen, Christina
dc.contributor.authorHahn, Friedrich
dc.contributor.authorKaufer, Benedikt B.
dc.contributor.authorNeipel, Frank
dc.contributor.authorEickhoff, Jan
dc.contributor.authorKlebl, Bert
dc.contributor.authorNam, Kiyean
dc.contributor.authorMarschall, Manfred
dc.date.accessioned2024-09-13T10:55:47Z
dc.date.available2024-09-13T10:55:47Z
dc.date.issued2024-01-23
dc.description.abstracthe repertoire of currently available antiviral drugs spans therapeutic applications against a number of important human pathogens distributed worldwide. These include cases of the pandemic severe acute respiratory coronavirus type 2 (SARS-CoV-2 or COVID-19), human immunodeficiency virus type 1 (HIV-1 or AIDS), and the pregnancy- and posttransplant-relevant human cytomegalovirus (HCMV). In almost all cases, approved therapies are based on direct-acting antivirals (DAAs), but their benefit, particularly in long-term applications, is often limited by the induction of viral drug resistance or side effects. These issues might be addressed by the additional use of host-directed antivirals (HDAs). As a strong input from long-term experiences with cancer therapies, host protein kinases may serve as HDA targets of mechanistically new antiviral drugs. The study demonstrates such a novel antiviral strategy by targeting the major virus-supportive host kinase CDK7. Importantly, this strategy focuses on highly selective, 3D structure-derived CDK7 inhibitors carrying a warhead moiety that mediates covalent target binding. In summary, the main experimental findings of this study are as follows: (1) the in vitro verification of CDK7 inhibition and selectivity that confirms the warhead covalent-binding principle (by CDK-specific kinase assays), (2) the highly pronounced antiviral efficacies of the hit compounds (in cultured cell-based infection models) with half-maximal effective concentrations that reach down to picomolar levels, (3) a particularly strong potency of compounds against strains and reporter-expressing recombinants of HCMV (using infection assays in primary human fibroblasts), (4) additional activity against further herpesviruses such as animal CMVs and VZV, (5) unique mechanistic properties that include an immediate block of HCMV replication directed early (determined by Western blot detection of viral marker proteins), (6) a substantial drug synergism in combination with MBV (measured by a Loewe additivity fixed-dose assay), and (7) a strong sensitivity of clinically relevant HCMV mutants carrying MBV or ganciclovir resistance markers. Combined, the data highlight the huge developmental potential of this host-directed antiviral targeting concept utilizing covalently binding CDK7 inhibitors.en_US
dc.identifier.citationYu, Wagner, Schütz, Jeon, Seo, Kim, Brückner, Kicuntod, Tillmanns, Wangen, Hahn, Kaufer, Neipel, Eickhoff, Klebl, Nam, Marschall. An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity. Pharmaceutics. 2024;16(2)en_US
dc.identifier.cristinIDFRIDAID 2261763
dc.identifier.doi10.3390/pharmaceutics16020158
dc.identifier.issn1999-4923
dc.identifier.urihttps://hdl.handle.net/10037/34709
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.journalPharmaceutics
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2024 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleAn Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivityen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)